#Pharma Conferences 2018

[mostlysignssomeportents]

This day in history

This Saturday (May 20), I’ll be at the GAITHERSBURG Book Festival with my novel Red Team Blues; then on May 22, I’m keynoting Public Knowledge’s Emerging Tech conference in DC.

On May 23, I’ll be in TORONTO for a book launch that’s part of WEPFest, a benefit for the West End Phoenix, onstage with Dave Bidini (The Rheostatics), Ron Diebert (Citizen Lab) and the whistleblower Dr Nancy Olivieri.

#15yrsago Ballad of a TCP Reset Packet https://arstechnica.com/staff/2008/05/free-ars-friday-song-ballad-of-the-tcp-reset-packet/

#15yrsago Bruce Sterling’s visionary novel Distraction: still brilliant a decade later https://memex.craphound.com/2008/05/17/bruce-sterlings-visionary-novel-distraction-still-brilliant-a-decade-later/

#10yrsago Gawker reporter claims to have seen video of Toronto Mayor Rob Ford smoking crack https://www.gawker.com/for-sale-a-video-of-toronto-mayor-rob-ford-smoking-cra-507736569

#10yrsago Company that oversees US “six-strikes” copyright shakedown has its company status revoked https://torrentfreak.com/six-strikes-anti-piracy-outfit-loses-company-status-faces-penalties-130515/

#5yrsago Star of racist deli rant identified as Trump-donating NYC lawyer Aaron Schlossberg https://gothamist.com/news/enraged-white-man-threatens-to-call-ice-on-women-for-speaking-spanish-in-manhattan-fresh-kitchen

#5yrsago Rising levels of a banned chemical are threatening the ozone layer (again) https://www.washingtonpost.com/news/energy-environment/wp/2018/05/16/someone-somewhere-is-making-a-banned-chemical-that-destroys-the-ozone-layer-scientists-suspect/

#5yrsago Student debt crisis watch: pay $18,000 of your $24,000 loan, owe $24,000 https://www.bustle.com/p/ive-paid-18000-to-a-24000-student-loan-i-still-owe-24000-9000788

#5yrsago For decades, it was an open secret that patients of USC’s only full-time gynecologist were complaining about sexual assaults during exams https://www.latimes.com/local/california/la-me-usc-doctor-misconduct-complaints-20180515-story.html

#5yrsago It’s laughably simple to buy thousands of cheap, plausible Facebook identities https://www.buzzfeednews.com/article/charliewarzel/heres-how-easy-it-is-to-buy-fake-facebook-profiles

#5yrsago A collaborative bibliography of “economic science fiction” https://edgeryders.eu/t/economic-science-fiction-a-selection-of-works-and-authors/8582

#5yrsago The £7 billion Carillion collapse has the UK government talking about breaking up the Big Four accounting firms https://www.independent.co.uk/news/business/news/big-four-accountancy-firms-broken-up-kpgm-pwc-deloitte-a8354911.html

#5yrsago America’s new aristocracy: the 9.9% and their delusion of hereditary meritocracy https://www.theatlantic.com/magazine/archive/2018/06/the-birth-of-a-new-american-aristocracy/559130/

#5yrsago New York surpasses Brexit London as the world’s second-hottest luxury property market https://www.mansionglobal.com/articles/hong-kong-new-york-and-london-top-world-luxury-markets-97360

#5yrsago How Big Pharma bribed docs to overprescribe opioids https://pluralistic.net/2022/05/17/dollars-for-docs/#slaughter

Catch me on tour with Red Team Blues in Toronto, DC, Gaithersburg, Oxford, Hay, Manchester, Nottingham, London, and Berlin!

[healthcaremarketanalysis]

Global Prefilled Syringes Market worth $8.6 billion by 2025

The size of global prefilled syringes market in terms of revenue was estimated to be worth $5.6 billion in 2020 and is poised to reach $8.6 billion by 2025, growing at a CAGR of 9.0% from 2020 to 2025. The research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Download PDF Brochure:

Increasing adoption of self-administered injectable drugs is expected to result in the segment occupying the majority of the industry share

The conventional Prefilled Syringes Market is estimated to have the largest market share by value. Growth of this segment can be attributed to the the advantages offered, such as safe administration, ease of use for both healthcare professionals and end users, reduced risk of contamination of the product, less waste of costly API, ease of manufacturing, improved dosing accuracy, and enhanced product differentiation when compared to vials is expected to drive the market growth.

By type, the safety prefilled syringes segment of prefilled syringes industry, is expected to grow at the highest CAGR during the forecast period

The safety prefilled syringes segment is expected to witness the highest growth during the forecast period primarily due to the rising geriatric population globally and availability of biological therapies for patients with chronic conditions and outsourcing of low-risk medical procedures for chronic patients alleviates some of the pressure on hospitals

Glass prefilled syringes is the largest material segment of the prefilled syringes industry

The glass prefilled syringes segment accounted for the largest share of the global industry in 2019. The large share of this segment is attributed to the significant benefits offered, such as prevention of oxygen and water vapor from interacting with drug compounds, compatibility with different filling machines, and seamless integration into pharmaceutical companies’ PFS operations.

Single-chamber prefilled syringes accounted for the largest share of the prefilled syringes industry, by design

The single-chamber prefilled syringes segment accounted for the largest share of the global industry in 2019. Market growth can largely be attributed to the significant advantages with the use of single-chamber prefilled syringes over vials, such as optimized API use with less overfill, reduced material requirements, less drug waste in clinical trials, and simple storage & disposal. Additionally, increasing adoption of self-administered parenteral drugs due to the increasing prevalence of chronic diseases and benefits offered by prefilled syringes.

Europe is the largest regional market for prefilled syringes

Europe is one of the major revenue-generating regions in the global market. Rising prevalence of chronic diseases, growth of the biologics and biosimilars market, technological advancements, geographical expansion by key manufacturers, aging population, and high adoption of self-injection devices are driving the demand for self-injectable prefilled syringes.  are the major factors driving the growth of the global market in Europe.

Global players operating in the global prefilled syringes market are Becton, Dickinson and Company (US), Gerresheimer (Germany), SCHOTT AG (Germany), West Pharmaceutical Services, Inc. (US), Baxter International Inc (US), Ompi (Italy), Catalent, Inc. (US), Weigao Group (China), Vetter Pharma International GmbH (Germany), Nipro Corporation (Japan), Elcam Medical (Israel), YPSOMED (Switzerland), Oval Medical Technologies (UK), SHL Medical AG (Switzerland), Terumo (Japan).

Recent Developments

In October 2018, Becton, Dickinson and Company launched the BD Intevi 1mL two-step disposable autoinjector.

In July 2020, Becton, Dickinson and Company entered into an partnership with Biomedical Advanced Research and Development Authority (BARDA) (US)

In July 2018, Becton, Dickinson and Company acquired Teva Medical Inc. (US)

[yourcientificgroup-blog]

Singapore Events | Drug Conferences | 2019

For more details send your Abstract: http://worldpharmaceuticalmeetings.com/abstract-submission.php

[saudade-mayari]

Hi! It’s me ☺️ I’m not the last anon but I want to become a psychiatrist, and ik it’s different working with physical health rather than mental health, but even so, do you have any tips on how to toughen up? Working with patients and other people in such a cutthroat environment will definitely be an enormous challenge for someone as sensitive as me. I’m a big crier!

OMG AVE. I CANT BELIEVE YOU’RE IN MY ASK BOX. SLIGHT FAN GIRLING ALERT IM SO SORRY.

during my clerkship year back in 2017-2018. I had a 2 months rotation in psychiatry. Maybe there are few things that I learned during those 2 months. However, this field is nowhere in my specialty since im honing myself in pediatrics for 2 yrs now.💜

—one thing I learned in psychiatry during my clerkship is the massive employment of variety treatment modalities like psychotherapy, psychosocial interventions and medications.

—generally in pediatrics the ones mentioned above are the common psychiatric diagnosis we do before we hand them over to psychiatrists.

—any pre med program is actually okay for psychiatry but it is always preferred to be psych and med bio (slight in pharmacy) and i truly understood that.

—first is babe try honing foundations in your pre med years. because either way you’re going to enter med school as well and you’re gonna have to experience some scopes that are far from psychiatry. although its only almost 20% of what we’ve learned in pre med it still helps. the foundation matters.

—general mental tip as a med student most especially in your preferred specialization is try your best on managing your anger during crisis. hard bcoz med school is literally filled with breakdowns and mental crisis but try your best to have a healthy coping mechanism. (eg. mine i wake up at 5am to watch sunrise while i memorize for the upcoming reválida)

—toughen up in a sense that do not put all the burdens to yourself. you’re going to deal one of the biggest and stereotyped crisis in the world so form your study group. reválidas and retdems aren’t new to you as well and for someone who wants to specialize in psychiatry, tackling statistics, data and analyzing researches with your peers is seriously important.

—on my 2 months of psychiatry dept, i learned that taking webinars, seminars and conferences is important. it is more than just physical application but mental analyzation as well and you need many many seminar participation in order to fully understand and scope more on your field of specialization.

—since psych is once of its basic foundations always remember that you can’t remain detached and objective when studying and analyzing in psychology. application to your peers, family members and personal life is always a key point.

—general and clinical pharmacology!!!! this too is one of the most important things i have learned as a major in pharmacy. CNS drugs, muscarinic and nicotinic receptors should be taken more seriously when going into field of specialization in psychiatry.

—pharmacology is real hard for us. for pharma students pharmacodynamics and kinetics will kill them. however, one of the tips that i still use up til now is keep reading and knowing your body clock. you don’t have to memorize an entire MOA of a drug. just know the drug classifications and you’ll be good to go in surviving pharmacology.

—i highlighted pharmacology because this is one of the controversial issues among stereotypes and as a future psychiatrist. mentally, physically and emotionally prepare yourself how to do a proper patient counseling via knowing the pharmacology of the drugs that you may prescribe in the near future.

—as a future psychiatrist, promote and introduce complimentary and alternative medicine. this would help you and your future patients to be in a broad domain of treating and healing resources that is not practiced in conventional medicine.

—during my clerkship in psychiatry, a senior resident doctor in psychiatry recommended complimentary and alternative medicine like manipulative, biologically based therapies and even body based therapies/practices. when I asked why... the senior resident told me that sometimes even patients who consult for their mental stability would doubt the treatments no matter what persuasion they did. he told me that it’s natural for a patient to be afraid so take consideration on suggesting therapies that wouldn’t require drugs and medications.

—lastly, failing and constant breakdowns will happen in med school no matter how hard you avoid it. that’s just the nutshell of medschool but it’s worth. DEFINITELY WORTH IT.

i dunno if this could help but i made this post for my moot who asked tips in surviving med school.

then upon clerkship on your 4th year in med school, you will have to deal with various rotations other than psychiatry so my previous post will somehow guide you to other decking.

with the current state we are now, wholeheartedly accept the passion and prove them that mental health is composed to many aspects of one’s wellness, social interaction, communication skills and the ability to express their emotions. 💜✨

[marrtins12]

Listen the best of all time podcast music to get entertain today

Listen Now

[runawaymarbles]

Most pharmaceutical companies dont want a cure to exist because then they dont make bank on their drugs- my professor who goes to all of the world conferences on the subject and talked about "cures" that were buried by big pharma

https://www.forbes.com/sites/quora/2018/09/10/some-think-big-pharma-is-suppressing-a-cure-for-cancer-heres-why-that-could-never-happen/#c8f02b3419c2

https://www.snopes.com/fact-check/dca-cancer-cure/

I find it incredibly difficult to believe every group studying chronic illness is agreeing to have their results suppressed. That’s thousands upon thousands of researchers, developers, etc.

Most people know someone who has had, say, cancer. So I assume most researchers have known someone who has had cancer. You think all of those people would agree to just... not say anything?

Worldwide?

The United States health care system is fucked up, definitely. It is also not the only healthcare industry in the world.

And again: every company is going to want to be the one to patent a new cure so they can charge us out the buttholes for it. (Wouldn’t a drug company much rather charge you a million dollars for a cure, then 10,000 for a hundred treatments, since you might up and die in the middle of them?)

If a big company and a little company are both making the same drugs, or competing for the same market, would the big one suppress the little one in order to get more of that crunchy crunchy government funding? Probably. I’d buy that. Is that inhibiting progress? Probably. Can I see how that would morph into “BIG PHARMA STOPPED US FROM CURING CANCER?” Easily.

But the idea that there are lots of full blown, tested, gen-u-ine cures to the most enduring health problems of our time out there and somehow, to keep selling chemo treatments, a couple drug companies have managed to keep quiet everyone who has ever worked on or been involved, to the point that the only sites I could find arguing for your side were, uh... shady and made by people enraged because they were sure there was a solution to their problem out there Somewhere?

It’s not impossible because we are living in an age of absolute buffoonery, but I find it very unlikely. Both for financial and logistical reasons.

[phroyd]

A judge in Oklahoma on Monday ruled that Johnson & Johnson had intentionally downplayed the dangers and oversold the benefits of opioids, and ordered it to pay the state $572 million in the first trial of a drug manufacturer for the destruction wrought by prescription painkillers.

The amount fell far short of the $17 billion judgment that Oklahoma had sought to pay for addiction treatment, drug courts and other services it said it would need over the next 20 years to repair the damage done by the opioid epidemic.

Still, the decision, by Thad Balkman of Cleveland County District Court, heartened lawyers representing states and cities — plaintiffs in many of the more than 2,000 opioid lawsuits pending across the country — who are pursuing a legal strategy similar to Oklahoma’s. His finding that Johnson & Johnson had breached the state’s “public nuisance” law was a significant aspect of his order.

Judge Balkman was harsh in his assessment of a company that has built its reputation as a responsible and family-friendly maker of soap, baby powder and Band-Aids.

In his ruling, he wrote that Johnson & Johnson had promulgated “false, misleading, and dangerous marketing campaigns” that had “caused exponentially increasing rates of addiction, overdose deaths” and babies born exposed to opioids.

Sabrina Strong, a lawyer for Johnson & Johnson, one the world’s biggest health care companies, said, “We have many strong grounds for appeal and we intend to pursue those vigorously.”

Johnson & Johnson, which contracted with poppy growers in Tasmania, supplied 60 percent of the opiate ingredients that drug companies used for opioids like oxycodone, the state argued, and aggressively marketed opioids to doctors and patients as safe and effective. A Johnson & Johnson subsidiary, Janssen Pharmaceuticals, made its own opioids — a pill whose rights it sold in 2015, and a fentanyl patch that it still produces.

Judge Balkman said the $572 million judgment could pay for a year’s worth of services needed to combat the epidemic in Oklahoma.

“We would have liked to walk out of here with $17 billion, but we’ve been able to put together a billion dollars,” Oklahoma’s attorney general, Mike Hunter, said at a news conference on Monday. He was referring to the cumulative amount from the Johnson & Johnson judgment and previous settlements with two other drug manufacturers that produce opioids. Earlier this year, Purdue Pharma and Teva Pharmaceuticals agreed to pay $270 million and $85 million, respectively.

“We’ve shown that J & J was at the root cause of this opioid crisis,” said Brad Beckworth, the lead attorney for the state. “It made billions of dollars from it over a 20-year period. They’ve always denied responsibility and yet at the same time they say they want to make a difference in solving this problem. So do the right thing: Come in here, pay the judgment.”

The case was also closely watched by some two dozen opioid makers, distributors and retailers that face more than 2,000 similar lawsuits around the country.

In a statement, Michael Ullmann, the general counsel and executive vice president of Johnson & Johnson, referring to the company’s pharmaceutical subsidiary, said that “Janssen did not cause the opioid crisis in Oklahoma, and neither the facts nor the law support this outcome.

“We recognize the opioid crisis is a tremendously complex public health issue,” he said, “and we have deep sympathy for everyone affected.”

The stocks of Johnson & Johnson and other opioid manufacturers rallied briefly in after-hours trading after the news, perhaps because some had anticipated a judgment of $1 billion or more. Johnson & Johnson stock was up about 4 percent in after-hours trading on Monday evening, and the stocks of Endo International, Mallinckrodt and Teva Pharmaceutical Industries all briefly spiked after the decision, although some fell again.

Oklahoma has suffered mightily from opioids. Mr. Hunter has said that between 2015 and 2018, 18 million opioid prescriptions were written in a state with a population of 3.9 million. Since 2000, his office said, about 6,000 Oklahomans have died from opioid overdoses, with thousands more struggling with addiction.

To calculate the Oklahoma award, Judge Balkman relied on the state’s detailed estimates of what it would cost to remediate the effects of the opioid epidemic. The state said it would need $893 million a year, or about $17 billion over 20 years.

The state’s case was argued by private lawyers whose sense of urgency was driven by personal tragedy — among them, they had seen a son, a business partner and friends succumb to opioids.

On the eve of trial, the lead attorney, Mr. Beckworth, of Austin, Tex., almost dropped out because his wife had just begun chemotherapy for breast cancer, but he said she urged him to stick with the case he “had been born to try.” “If you have an oversupply,” he said in his opening argument, “people will die.”

Reading a summary of his decision in court in Norman, Okla., Judge Balkman said Johnson & Johnson had an outsize impact on the state’s epidemic, though its share of opioid sales was scarcely 1 percent of the market.

“The critical finding is that Johnson & Johnson engaged in false, deceptive and misleading marketing,” said Abbe R. Gluck, who teaches health policy and law at Yale Law School.

From 2000 through 2011, members of Johnson & Johnson’s sales staff made some 150,000 visits to Oklahoma doctors, focusing in particular on high-volume prescribers, the state said. In addition, the pharmaceutical giant supplied most of the nation’s opioid material to other drug manufacturers, refined by one of its companies from a variety of poppy that Johnson & Johnson developed and grew in Tasmania.

Johnson & Johnson, represented by Larry D. Ottaway, an Oklahoma lawyer, argued its case with an eye toward appellate courts. Indeed whether Judge Balkman’s verdict will survive scrutiny is uncertain: State and possibly federal appeals judges may take a skeptical view of the state’s legal theory and the extent of the company’s liability.

During the trial, Johnson & Johnson said blame for the epidemic could not fairly be placed on one company with such modest sales, whose drugs were approved and strictly regulated by state and federal agencies.

Johnson & Johnson said that the state could not show how Oklahoma’s problems, which the company said arose from the diversion of hydrocodone and oxycodone, could be linked to Janssen, which did not make those drugs. It cited black-box warnings on Duragesic, its fentanyl patch, which cautioned about the potential for abuse and addiction. And it said the state had not identified any doctor who had been misled by the company about the dangers of opioids.

But Judge Balkman wrote that he was persuaded by the state’s legal theory. The judge found that Johnson & Johnson perpetuated a “public nuisance,” substantially contributing to an ongoing public health crisis that could take decades to abate.

Public nuisance laws are usually applied in cases where something interferes with a right common to the general public, traditionally roads, waterways or other public areas. Recently, plaintiffs have used the laws to press claims involving lead paint, guns or water or air pollution, with mixed results. Oklahoma’s public nuisance statute is relatively broad, and the state argued that Johnson & Johnson substantially interfered with public health.

Johnson & Johnson’s lawyers contended that the state was contorting public nuisance law to the point of being unrecognizable.

Lawyers representing more than 2,000 cities, counties and other jurisdictions with opioid cases pending in federal court were cheered by Judge Balkman’s ruling. In a statement, they said: “While public nuisance laws differ in every state, this decision is a critical step forward.”

Judge Balkman’s ruling comes only two months before the first federal opioid trial is to begin in Cleveland, brought by two Ohio counties against an array of manufacturers, distributors and pharmacies.

Now that the value of the Oklahoma case has been determined, settlement negotiations may quicken between industry defendants and two large groups of plaintiffs — one, representing thousands of cities and counties, consolidated in federal court in Cleveland, and the other, a coalition of states.

But the seven-week Oklahoma trial, which began on May 28, was also singular in some ways. Judge Balkman, an elected jurist and former state legislator, presided over the case. By contrast, much of the forthcoming Ohio trial, which includes other claims, will be heard by a jury.

Also, the pending federal case in Ohio involves numerous defendants, while Oklahoma made its case in court against just Johnson & Johnson.

The level of proof required by the state to back up its allegation that Johnson & Johnson was the “kingpin” of the opioid epidemic required that it demonstrate that the company was responsible for most of the opioid-related damage — from criminal justice to health care, foster care and treatment facilities.

The state said that the company aggressively promoted the safety of opioids generally, through campaigns tailored for women, teenagers and veterans. The company engaged with “front groups” of pain patients and pain medicine specialists, who insisted the drugs were effective for quotidian pain and downplayed the risk of addiction.

“Judge Balkman has affirmed our position that Johnson & Johnson maliciously and diabolically created the opioid epidemic in our state,” Mr. Hunter said.

Phroyd

[stoweboyd]

Work Futures Minipost - A No-Win Situation

| HR Lies | Gigging While Gigging | Bad Interviews | Future of Work Disconnect | Kevin Kelly |

Beacon NY - 2019-05-30 — I recently pulled up Kevin Kelly's Futurist's Dilemma post in a conversation. Kelly said 'a futurist can’t win'. See his quote of the day below.

:::

This is a summary of a longer post at workfutures.substack.com. Feel free to share it with others.

Consider becoming a paid sponsor to support our work, and to receive in-depth investigative reporting and discounts to other events, reports, and activities.

And paid sponsors gain access to our new members community. Visit members.workfutures.org to request a trial membership.

:::

Our new publication, On The Horizon, is dedicated to help spread greater understanding of the economics, structure, and behavior of platform ecosystems, and the corresponding reordering of business operations and organization. Sign up for the OTH weekly newsletter to be notified about new articles, interviews, events, and other news from the exploding domain of platform ecosystems.

Stories

What Really Helps Employees to Improve (It’s not Criticism) | Knowledge@Wharton wrote about Marcus Buckingham's recent keynote at the Wharton People Analytics Conference, where he called most of the premises of HR 'lies':

In Nine Lies About Work, Buckingham and [Ashley] Goodall argue that corporations’ increasing insistence that people be well-rounded and accept others’ feedback comes from the desire of top leaders to achieve simplicity and order. While this desire is understandable, they write, it “easily shades into a desire for conformity.” Before long, that conformity threatens to extinguish individuality.

:::

Uber Drivers Seek Extra Cash Working for House Flippers | Will Parker and Cameron McWhirter report on gigging while gigging, where house-flipping companies pay Uber and Lyft drivers to take pictures of dilapidated houses.

:::

5 dumb hiring trends | Anisa Purbasari Horton pulls five useless categories of interview methods, like unstructured interviews, which introduce all sorts of bias into hiring.

:::

Ongoing survey: The future of work | MIT Technology Review shared results of a survey, and these two questions demonstrate a huge disconnect in how companies are supposedly 'preparing' for the future of work. As just one example, creativity is called out as a skill for the future by 36% in the bottom chart, but there is no obvious creativity-oriented initiative in the top chart. 'Everybody be creative!' probably won't work.

Quote of the Day

[Arthur C] Clarke says that if you find a prediction reasonable, then it is probably wrong, because the future is not reasonable; it is fantastic! But if you could return from the future with the exact truth about what will happen, no one would believe you because the future is too fantastic! By fantastic he means issuing from the realm of fantasy and the imagination — beyond what we expect.

This is the futurist’s dilemma: Any believable prediction will be wrong. Any correct prediction will be unbelievable. Either way, a futurist can’t win. He is either dismissed or wrong.

| Kevin Kelly, The Futurist’s Dilemma

Elsewhere

A post from On The Horizon, The Limits of Digital: Ideas, Creativity, and Cultural Reformation is being promoted on Medium:

Our curators just read your story, The Limits of Digital: Ideas, Creativity, and Cultural Reformation, that you submitted for review. Based on its quality, they selected it to be recommended to readers interested in Artificial Intelligence, Economy, Productivity, and Work across our homepage, app, topic pages, and emails.

This story will be distributed as part of Medium’s metered paywall, so feel free to share it with your fans using your Friend Link — this will ensure they don’t see the paywall. Your Friend Link is: https://medium.com/p/the-limits-of-digital-ideas-creativity-and-cultural-reformation-27d96196f29a?source=email-5ca7a56598a7--writer.postDistributed&sk=64e5dc29ba3252d86258008799ae7b83

:::

Bernie Sanders backs 2 policies to dramatically shift corporate power to U.S. workers | Jeff Stein reports on new ideas from Presidential candidates eBernie Sanders about making business for democratic and egalitarian:

Sanders said his campaign is working on a plan to require large businesses to regularly contribute a portion of their stocks to a fund controlled by employees, which would pay out a regular dividend to the workers. Some models of this fund increase employees’ ownership stake in the company, making the workers a powerful voting shareholder. The idea is in its formative stages and a spokesman did not share further details.

Sanders also said he will introduce a plan to force corporations to give workers a share of the seats on their boards of directors. Sen. Elizabeth Warren (D-Mass.), another 2020 presidential candidate, proposed a similar idea last year.

[odohring-blog]

Previous academic work and contributions to pharmaceutical conferences

I am Orlando Dohring. This page lists previous academic work and contributions to pharmaceutical conferences. Firstly, links to those documents are provided. Then, further down, I list the abstracts for those documents. Academic work: - PhD Thesis: Identification of breed contributions in crossbred dogs

  - MPhil Thesis: Peak selection in metabolic profiles using functional data analysis

  Contributions to Statisticians in the Pharmaceutical Industry (PSI) conference: - Talk PSI 2018: Introduction to Machine Learning for Longitudinal Medical Data

- Poster PSI 2017: Big Data Meets Pharma

- Poster PSI 2016: Sparse Principal Component Analysis for clinical variable selection in longitudinal data

- PhD Thesis Abstract: Identification of breed contributions in crossbred dogs: There has been a strong public interest recently in the interrogation of canine ancestries using direct-to-consumer (DTC) genetic ancestry inference tools. Our goal is to improve the accuracy of the associated computational tools, by developing superior algorithms for identifying the breed composition of mixed breed dogs. Genetic test data has been provided by Mars Veterinary, using SNP markers. We approach this ancestry inference problem from two main directions. The first approach is optimized for datasets composed of a small number of ancestry informative markers (AIM). Firstly, we compute haplotype frequencies from purebred ancestral panels which characterize genetic variation within breeds and are utilized to predict breed compositions. Due to a large number of possible breed combinations in admixed dogs we approximately sample this search space with a Metropolis-Hastings algorithm. As proposal density we either uniformly sample new breeds for the lineage, or we bias the Markov Chain so that breeds in the lineage are more likely to be replaced by similar breeds. The second direction we explore is dominated by HMM approaches which view genotypes as realizations of latent variable sequences corresponding to breeds. In this approach an admixed canine sample is viewed as a linear combination of segments from dogs in the ancestral panel. Results were evaluated using two different performance measures. Firstly, we looked at a generalization of binary ROC-curves to multi-class classification problems. Secondly, to more accurately judge breed contribution approximations we computed the difference between expected and predicted breed contributions. Experimental results on a synthetic, admixed test dataset using AIMs showed that the MCMC approach successfully predicts breed proportions for a variety of lineage complexities. Furthermore, due to exploration in the MCMC algorithm true breed contributions are underestimated. The HMM approach performed less well which is presumably due to using less information of the dataset. - MPhil Thesis Abstract: Peak selection in metabolic profiles using functional data analysis: In this thesis we describe sparse principal component analysis (PCA) methods and apply them to the analysis of short multivariate time series in order to perform both dimensionality reduction and variable selection. We take a functional data analysis (FDA) modelling approach in which each time series is treated as a continuous smooth function of time or curve. These techniques have been applied to analyse time series data arising in the area of metabonomics. Metabonomics studies chemical processes involving small molecule metabolites in a cell. We use experimental data obtained from the COnsortium for MEtabonomic Toxicology (COMET) project which is formed by six pharmaceutical companies and Imperial College London, UK. In the COMET project repeated measurements of several metabolites over time were collected which are taken from rats subjected to different drug treatments. The aim of our study is to detect important metabolites by analysing the multivariate time series. Multivariate functional PCA is an exploratory technique to describe the observed time series. In its standard form, PCA involves linear combinations of all variables (i.e. metabolite peaks) and does not perform variable selection. In order to select a subset of important metabolites we introduce sparsity into the model. We develop a novel functional Sparse Grouped Principal Component Analysis (SGPCA) algorithm using ideas related to Least Absolute Shrinkage and Selection Operator (LASSO), a regularized regression technique, with grouped variables. This SGPCA algorithm detects a sparse linear combination of metabolites which explain a large proportion of the variance. Apart from SGPCA, we also propose two alternative approaches for metabolite selection. The first one is based on thresholding the multivariate functional PCA solution, while the second method computes the variance of each metabolite curve independently and then proceeds to these rank curves in decreasing order of importance. To the best of our knowledge, this is the first application of sparse functional PCA methods to the problem of modelling multivariate metabonomic time series data and selecting a subset of metabolite peaks. We present comprehensive experimental results using simulated data and COMET project data for different multivariate and functional PCA variants from the literature and for SGPCA. Simulation results show that that the SGPCA algorithm recovers a high proportion of truly important metabolite variables. Furthermore, in the case of SGPCA applied to the COMET dataset we identify a small number of important metabolites independently for two different treatment conditions. A comparison of selected metabolites in both treatment conditions reveals that there is an overlap of over 75 percent. - Talk PSI 2018 Abstract: Introduction to Machine Learning for Longitudinal Medical Data: In the era of big data, there has been a surge in collected biomedical data, which has provided ample challenges for distributed computing but also posed novel inference questions. Application areas range from Bioinformatics (disease diagnosis from microarray data, drug discovery from molecular compounds), medical imaging (brain reconstruction, organ segmentation, tumour detection from MRI/CT/X-Ray images), sensing (anomaly detection, human activity recognition from images, wearable devices), public health (prediction of epidemic alerts from social media data and meta-information in mobile devices) to healthcare informatics (inference regarding length of hospital stay, readmission probability within next days, mortality prediction from electronic health records). Classical machine learning techniques, such as logistic regression, neural networks, support vector machine and Gaussian processes performed very well in non-temporal prediction tasks but typically relied on the independence assumption. However, many recent application have longitudinal context in the form of short- and long-term dependencies, e.g. local spatial features in brain images, sentiment in medical reports and summaries of medical research. Hidden Markov Models proved popular to model longitudinal data but increasingly become less computationally feasible for a large number of hidden states. Recently, advances in parallel computing led to widespread use of deep learning approaches, such as recurrent neural networks and convolutional networks, and attracted attention due to their impressive results on sequence data. Finally, we will look in more detail at a case study from healthcare analytics which infers disease type from multiple irregularly sampled longitudinal observations, such as blood pressure, heart rate and blood oxygen saturation. - Poster PSI 2017 Abstract: Big Data Meets Pharma: In this work we present a tutorial introduction to show how SAS can be leveraged for large datasets in the pharmaceutical sector: Big data plays an increasingly important role within drug compound discovery, genomic data analysis in clinical trials and real-time streaming data from wearable devices or sensors which monitor patients’ health and treatment compliance. SAS adopted Hadoop as highly scalable data platform for data warehouse operations, descriptive statistics and statistical analysis with a bias towards machine learning approaches. However, Hadoop’ MapReduce framework is slow and batch-oriented which is not very suitable for iterative, multi-step parallel algorithms with a focus on in-memory computations. To address these limitations SAS added layers for in-memory computation, interactive data queries using a SQL variant, support for streaming analytics and predictive models implemented in SAS Visual Statistics/ Analytics. In the data science sector, the similar open-source Apache Spark project with its machine learning library MLlib is commonly used. Both Visual Statistics and MLlib have implementations for linear/logistic regression, decision-tree based classifiers, and clustering. Furthermore, SAS focusses on group-by processing and GLMs while MLlib has methods for feature extraction, dimensionality reduction, SVM classifiers, matrix completion and basic hypothesis tests. At the moment the SAS Hadoop implementation is a good selection for data management and dataset derivations which often can be parallelized. However, currently there is lack of procedures typically in pharmaceutical statistics, such as mixed effect models for repeated measurements analysis or survival analysis models. - Poster PSI 2016 Abstract: Sparse Principal Component Analysis for clinical variable selection in longitudinal data: Background: Data collection is a time-consuming and expensive process. To minimise costs and reduce time, statistical methods can be applied to determine which variables are required for a clinical trial. Principal component analysis (PCA) is a popular exploratory technique to select a subset of variables at one timepoint. For multiple timepoints, typically each variables’ measurements are aggregated, which ignores temporal relationships. An alternative method is Sparse Grouped Principal Component Analysis (SGPCA), which also incorporates the temporal relationship of each variable.  SGPCA is based on ideas related to Least Absolute Shrinkage and Selection Operator (LASSO), a regularised regression technique, with grouped variables. SGPCA selects a sparse linear combination of temporal variables where each patient is represented as short multivariate time series which are modelled as a continuous smooth function of time using functional data analysis (FDA). Aim: Compare the ability of the PCA and SGPCA to identify required variables for clinical trials. Methods PCA and SGPCA will be applied to a longitudinal clinical dataset to select required variables.  We will compare the required variables, and the amount of variability retained for each technique under the SGPCA model. Conclusion This research will provide awareness of techniques to identify required variables in clinical trials, and aims to demonstrate the potential benefit of incorporating the temporal relationships in variable selection.

[eretzyisrael]

TEL AVIV (Reuters) - Israel’s Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson’s disease, expects to start earning money from the program sometime in 2019.

Jeffrey Meckler, chief executive of Israel's Intec Pharma holds up their long-lasting pill to treat Parkinson's disease, during an interview with Reuters in Tel Aviv, Israel November 7, 2018. REUTERS/Steven Scheer

Intec recently completed enrolling 462 patients for a Phase III trial for the pill that opens up like an accordion, with the levodopa drug remaining in the stomach for 8-12 hours, requiring fewer doses a day. Results are expected in mid-2019.

The Phase II trial showed a 45 percent reduction in “daily off time,” which gave patients more than two extra hours a day of movement.

“I feel very comfortable that we have an approvable program here. I would like to see as big an effect size as possible, but there is commercial viability at any effect size,” Jeffrey Meckler, Intec’s chief executive, told Reuters after a news conference on Wednesday.

“I hope next year we will be able to monetize value out of the Parkinson’s program, whether that is the sale of the company, sale of the program or a license partnership,” said Meckler, who took over in July 2017.

He said a large number of Parkinson’s companies were interested in the program but he declined to elaborate.

Assuming a 10 percent market share, Meckler said: “We have a drug that is worth more than $300 million a year.”

The drug would likely compete with Amneal Pharmaceuticals’ Rytary, which also reduces the amount of off-time.

Intec is also looking at a pill-based delivery for medical cannabis and has begun early stage trials.

“The cannabinoid program has much bigger potential than Parkinson’s,” Meckler said, adding the company aimed to license out drug delivery of medical cannabis prior to Phase III trials.

Intec’s strategy is to look for existing drugs and put them into its delivery platform, in which medicine is folded up in a film with layers that opens like an accordion.

Intec is working on trying to adapt its platform for an undisclosed drug from Novartis and a decision is expected on its viability in early 2019, said Meckler.

The Nasdaq-listed company raised $35 million in the second quarter, helping to fund the Parkinson’s trial. While not yet profitable, Intec had $66 million in cash at the end of June and is burning about $10 million a quarter.

“We don’t expect to raise money again before the Parkinson’s data” next year, Meckler said.

Reporting by Steven Scheer; Editing by Mark Potter

Our Standards:

The Thomson Reuters Trust Principles.

[mostlysignssomeportents]

Four Thieves Vinegar Collective: DIY epipens were just the start, now it's home bioreactors to thwart Big Pharma's price-gouging

When last we met the Four Thieves Vinegar collective -- a group of anarchist scientists who combine free/open chemistry with open source hardware in response to shkrelic gouging by pharma companies -- they were announcing the epipencil, a $30 DIY alternative to the Epipen, Mylan's poster-child for price-gouging and profiteering on human misery.

It's been two years since the epipencil and Four Thieves has been been busy.

Michael Laufer is one of the founding Four Thieves, and he's just presented a wide-ranging look at the Collective's technical accomplishments at HOPE, the Hackers on Planet Earth conference held every two years at New York's Hotel Pennsylvania.

Their main accomplishments involve the Apothecary Microlab, a DIY automated chemistry robot that you download and 3D print and assemble, using common hardware, electronics, and chemistry components. With the Microlab and the right chemicals, you can synthesize a variety of lifesaving drugs.

Home pharma manufacturing is not without risks -- you could easily end up making poison instead of medicine. But as Daniel Oberhaus points out in his Motherboard profile of Laufer, the Four Thieves have made amazing strides in harm reduction in drug synthesis. Using a database from a startup called Chematica, they mined 250 years' worth of organic chemistry history to find the safest-possible synthesis paths to the molecules they were trying to synthesize (unfortunately, Merck bought out Chematica and took the database proprietary, though there's a darkweb site with a password-protected, leaked version of the Chematica database that Laufer would like your help in breaking).

Right now, the Microlab can produce five drugs, including Naloxone (which saves the lives of people dying of opiod overdoses, and which uses oxymorphone bought on the street as a precursor, "making medicine from poison"); and cabotegravir (an experimental drug that prevents the spread of HIV from needle-sharing, which the collective makes available to heroin dealers to cut their products with).

They've got all kinds of ambitious plans, too. They're investigating using books as a medium for growing GM mycelia that could devour the cellulose in the paper and produce precursors; these books could be mailed at media rates between biohackers in a postal P2P system they call "biotorrents" (they're also thinking of using CDs as petri dishes, taking advantage of standard mailers and packaging). They're planning a work-focus on rare and orphan disease, and blockbuster drugs like Solvadi, the $84,000, one-shot Hep C cure.

The whole thing has the ring of OG hacker groups like Cult of the Dead Cow, as brilliant at media as they were at tech.

https://boingboing.net/2018/07/27/theft-to-prevent-murder.html

[cricsart]

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

[rootsanalysis-blog]

The biosensors market focused on drug discovery and development is projected to grow at an annualized rate of 9% during the period 2022-2035

In recent years, the use of biosensors in drug discovery has been on the rise, driven by several technological advancements and the growing demand for inexpensive and effective techniques for analyzing potential drug candidates.

 Roots Analysis has announced the addition of “Biosensors Market: Focus on Drug Discovery and Drug Development, 2022 - 2035” report to its list of offerings.

 A number of drug developers are already using novel biosensors for various drug discovery applications to address the concerns associated with high rate of failures of drug development programs and requirement of high capital investments. As the adoption of biosensors, specifically for drug discovery, increases amongst innovators in the pharma and biopharma industry, lucrative opportunities are expected to be created for players engaged in the biosensors for drug discovery market.

  Key Market Insights

 Currently, more than 80 biosensors are being developed by various stakeholders, across the world

Majority of the biosensors (64%) engaged in this domain are optical biosensors, followed by electrochemical biosensors (25%), quartz crystal microbalance biosensors (5%) and thermal biosensors (5%). Close to 95% of the biosensors are used for lead identification step in drug discovery. Further, 15% of the biosensors claim to support all the steps in drug discovery.

 Over USD 1.2 billion invested in various domain focused initiatives, since 2018

Specifically, in 2021, industry players raised close to USD 600 billion. In addition, majority of the companies (66%) primarily received funding through venture capital rounds. Further, around 60% of the total funding instances were reported by players headquartered in the US.

 In recent years, several global events related to biosensors in drug discovery were organized

Majority of the events related to biosensors in drug discovery were organized in Europe (45%). It is worth highlighting that the main agenda of these events was to discuss the development and challenges associated with the biosensors in drug discovery domain.

 370+ patents related to biosensors in drug discovery have been granted / filed between 2018-2022

R&D activity related to biosensors in drug discovery is largely concentrated in North America, considering the fact that 70% of the total number of patents were filed in this region. In addition, most of the patents in this domain are granted patents (55%), followed by patent applications (44%).

 North America and Europe are anticipated to capture over 70% of the market share, by 2035

In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (10%) in the long term. Further, in 2035, biosensors market for drug discovery applications for academic / research institutes is expected to capture the majority share (~60%) of the total market.

 To request a sample copy / brochure of this report, please visit

https://www.rootsanalysis.com/reports/global-biosensors-market/request-sample.html

 Key Questions Answered

§  Who are the key players engaged in the biosensors in drug discovery market?

§  What is the relative competitiveness of different biosensors being developed for drug discovery applications?

§  What are the key agenda items being discussed in various global events / conferences related to biosensors in drug discovery?

§  What is the focus area of the ongoing research activity related to biosensors in drug discovery?

§  How is the intellectual property landscape for biosensors in drug discovery likely to evolve in the foreseen future?

§  What are the factors that are likely to influence the evolution of this market?

§  How is the current and future market opportunity likely to be distributed across key segments?

 The financial opportunity within the biosensors in drug discovery market has been analyzed across the following segments:

 §  Type of Biosensor

§  Optical

§  Electrochemical

§  Thermal

§  Others

 §  Type of End User

§  Academic / Research Institutes

§  Industry Players

 §  Key Geographical Regions 

§  North America

§  Europe

§  Asia-Pacific

§  Latin America

§  MENA

§  Rest of the World 

 The report features inputs from eminent industry stakeholders, according to whom, continuous growth of biosensors market for drug discovery applications is primarily driven by the increasing adoption for such products. The report includes detailed transcripts of discussions held with the following experts:

§  Bill Rader (Chief Executive Officer, Efferent Labs)

§  Anne Marie Quinn (Chief Executive Officer, Montana Molecular)

§  Laurent Sabbagh (Associate Director and Head of Biology, Domain Therapeutics).

The research includes profiles of key players (listed below); each profile features a brief overview of the company, details related to its biosensor product portfolio, recent developments and an informed future outlook.

§  Agilent Technologies

§  Axion Biosciences

§  BioNavigations

§  Creoptix  

§  Cytiva

§  Dynamic Biosensors

§  Malvern Panalytical

§  Microvacuum

§  Sartorius

§  Tempo Bioscience

 For additional details, please visit 

https://www.rootsanalysis.com/reports/global-biosensors-market.html or email sales@rootsanalysis.com

 You may also be interested in the following titles:

1.       Targeted protein degradation market, 2022-2035

2.       Cell Therapy Manufacturing Market, 2021-2030

3.       Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

  Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

[rankertopanwar]

лаптопи на промоция

Welcome to AZO.BG!

Как се поръчва?

Мога ли да пазарувам онлайн без регистрация?

Трябва ли ми кредитна карта за да пазарувам онлайн?

Търсене на продукт

Избор на опция (цвят, размер и т.н.) на стока

Общи условия за пазаруване в AZO.BG

Информация за АЗОНЛАЙН ЕООД

Виж Всички

Доставка

Как се доставят стоките?

Проследяване на поръчка

Получаване на стоката

Получаване от офис на куриер

С кои куриерски фирми се доставят пратките

Виж Всички

Плащане

Трябва ли ми кредитна карта за да пазарувам онлайн?

Плащане при доставка

Плащане през PayPal.com

Покупка на изплащане с TBI

Виж Всички

Гаранция

Гаранционен срок на стоките

Подаване на рекламация на стока

GSM телефонът ми даде дефект, какво да направя?

Сервизиране на стока

Обърнете се към нас или към сервиз от гаранционната карта

Виж Още

Получаване от рекламация

Виж Всички

Бонус програма

Какво са Бонус точките?

Как се печелят точки?

Валидност на бонус точките и подаръчните ваучери

Виж Всички

Лични данни

Какви бисквитки използваме?

Какво е бисквитки?

Какви лични данни събираме?

Как са защитени личните данни?

Какви са правата ви за личните данни?

Виж Всички

fourteenth Global Biomarkers Summit (Biomarker Summit 2018)

October 18-19, 2018

Amsterdam, Netherlands

150+ representatives from Global Pharma and Bio Pharma Companies. CROs, emergency clinics, Biotech firms, famous establishments and Universities are supposed to take part at this Biomarker Summit. 30+ contextual analyses, introductions, board conversations, whole meetings, Poster Presentations, e-Poster Presentations, Young Researcher Forums will be planned to talk about the latest things, issues and novel disclosures in Biomarker Discovery, Biomarker research, clinical uses of Biomarkers, sidekick diagnostics, customized medication, Clinical and Translational Research in Biomarkers and so forth. To energize the Young Researchers across the globe, Global Biomarker Congress concocts the Young Researcher Forum (YRF), Best banner and Oral Presentation Awards and Young Researcher grants.

This Global Biomarker Summit will address the most recent patterns, challenges in Biomarker Discovery to improvement, Translational Biomarker exploration to Commercialization of Biomarkers. Significant meetings of this Biomarker Conference will zero in on Biomarker disclosure and approval, Next-age Sequencing (NGS), Biomarkers assessment, Biomarkers in illness conclusion and anticipation, Commercialization of Biomarkers, Biomarker endorsement, Biomarkers in Clinical Trials, Biomarkers in Drug Discovery, Functional genomics and cytogenetic biomarkers, procedures to expand biomarker ID, biomarkers applications in Nano science, difficulties of clinical interpretation, Companion Diagnostics, Reimbursement strategy in Biomarker research, Cell free Biomarkers in Disease determination and forecast and so forth.

Biomarkers Summit energetically welcome every one of the specialists working in the space of Biomarkers and related field to its forthcoming fourteenth Global Biomarker Summit (Biomarker Summit 2018), booked from October 18-19, 2018 Amsterdam, Netherlands.

Malignant growth is the subsequent driving reason for death overall and in all areas of the world. Disease is hazardous attributable to its capacity to spread around the body.

Visite for more info. :- https://azo.bg/bitova-tekhnika/gotvarski-uredi/fritjurnici

[serosyndicatbloodunion]

ALTERNATE ENDINGS, ACTIVIST RISINGS | Résurgences activistes et d’autres fins possibles Programme de courts métrages sur l’activisme contemporain du milieu VIH/sida en Amérique All new 2018 videos from the iconic annual VisualAIDS project DAY WITH(OUT) ART by: ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, VOCAL NY Thurs.Jeudi.29.NOV.19H00 | FREE Concordia University Amphithéâtre du Pavillon EV 1e étage | 1515 rue Ste-Catherine Ouest, Montréal | local EV1.605 Biscuits + thé | Tea + cookies: 18H30; Film projection de films: 19H. Suivi d’une discussion animée par le | post-screening discussion hosted by: SéroSyndicat/BloodUnion.  

Event made possible by Karen Herland, Concordia University instructor for HIV/AIDS: An Interdisciplinary Introduction to Scientific Social and Cultural Aspects, part of the Interdisciplinary Studies in Sexuality Program

More on Visual AIDS: http://visualaids.org/projects/detail/alternate-endings-activist-risings La traduction des descriptions des films et du projet DAY WITH(OUT) ART sera disponible le 19 novembre seulement. From VISUALAIDS: ALTERNATE ENDINGS, ACTIVIST RISINGS is the 29th iteration of Visual AIDS’ longstanding Day With(out) Art project. Highlighting the impact of art in contemporary AIDS activism and advocacy, the program features new short videos from six inspiring community organizations and collectives—ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, and VOCAL NY. ALTERNTE ENDINGS, ACTIVIST RISINGS seeks to reflect the persisting urgencies of today’s HIV/AIDS epidemic, including HIV criminalization, Big Pharma, homelessness, and the disproportionate effects of HIV on marginalized communities. At a moment of growing interest in the histories of AIDS activism, ALTERNATE ENDINGS, ACTIVIST RISINGS foregrounds contemporary engagements between activists, artists, and cultural workers on the front lines.

RÉSURGENCES ACTIVISTES ET D’AUTRES FINS POSSIBLES souhaite souligner l’importance et l’impact de l’art sur l’activisme contemporain du milieu VIH/Sida nord-américain à travers un programme de courts-métrages récents provenant de six organismes communautaires et collectifs de premier plan: ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, et VOCAL NY. Le programme présente une sélection de stratégies organisationnelles diverses et variées, de l’action directe aux mouvements nationaux (américains) en passant par les prestataires de services communautaires, tout en incorporant l’importance des pratiques artistiques dans les réponses activistes face à la crise actuelle du sida.

RÉSURGENCES ACTIVISTES ET D’AUTRES FINS POSSIBLES met en lumière les urgences chroniques de l’épidémie de VIH/Sida contemporaine, notamment la criminalisation des personnes séropositives, le lobby des grands groupes pharmaceutiques, l’itinérance et les effets disproportionnés que le VIH a sur les communautés marginalisées. Alors qu’il existe un intérêt grandissants pour les histoires de l’activisme en milieu VIH, RÉSURGENCES ACTIVISTES ET D’AUTRES FINS POSSIBLES révèle les combats contemporains que portent les activistes, artistes et producteurs.trices d’art sur le terrain.

Films synopses and more on DAY WITH(OUT) ART: ALTERNATE ENDINGS, ACTIVIST RISINGS highlights the impact of art in AIDS activism and advocacy today by commissioning compelling short videos from six inspiring community organizations and collectives—ACT UP NY, Positive Women’s Network, Sero Project, The SPOT, Tacoma Action Collective, and VOCAL NY. The program represents a wide range of organizational strategies, from direct action to grassroots service providers to nation-wide movement building, while considering the role of creative practices in activist responses to the ongoing AIDS crisis. ALTERNATE ENDINGS, ACTIVIST RISINGS seeks to reflect the persisting urgencies of today’s HIV/AIDS epidemic by pointing to pressing and intersecting political concerns, including HIV criminalization, Big Pharma, homelessness, and the disproportionate effects of HIV on marginalized communities. At a moment of growing interest in the histories of AIDS activism, ALTERNATE ENDINGS, ACTIVIST RISINGS foregrounds contemporary engagements between activists, artists, and cultural workers on the front lines. Commissioned Organizations AIDS Coalition to Unleash Power (ACT UP) NY (New York, NY) is a diverse, non-partisan group of individuals, united in anger and committed to direct action to end the AIDS crisis. ACT UP was formed in 1987 in response to social neglect, government negligence and the complacency of the medical establishment during the 1980s. Soon it found itself needing to fight corporate greed, lack of solidarity and various forms of stigma and discrimination at home and abroad. ACT UP fights for: sustained investment in research for new medicines and treatments for HIV/AIDS and related co-infections; equitable access to prevention and care for HIV/AIDS and healthcare, in general; tackling the structural drivers of the HIV/AIDS epidemic, such as stigma, discrimination and poverty. Positive Women’s Network – USA (PWN) is a national membership body of women living with HIV and allies that exists to strengthen the strategic power of all women living with HIV in the United States. Founded in 2008 by 28 diverse women leaders living with HIV, PWN-USA develops a leadership pipeline and policy agenda that applies a gender lens to the domestic HIV epidemic grounded in social justice and human rights. Every day, PWN-USA inspires, informs and mobilizes women living with HIV to advocate for changes that improve lives and uphold rights. Sero Project is a national network of people with HIV and allies fighting for freedom from stigma and injustice. Sero is particularly focused on ending inappropriate criminal prosecutions of people with HIV, including for non-disclosure of their HIV status, potential or perceived HIV exposure or HIV transmission. Sero co-produces the biennial HIV is Not a Crime conference, which provides advocates from across the country with training on strategies and best practices for repealing laws that criminalize people living with HIV. Safe Place Over Time (The SPOT) (Jackson, MS) is dedicated to providing services and opportunities for wellness, empowerment, and leadership to young men in Jackson, Mississippi. The program aims to improve health outcomes and reduce new cases of HIV among African Americans who are disproportionately affected by the epidemic. The SPOT strives to be a safe place for young men to openly discuss issues and challenges and to work to improve their quality of life and to promote the concept of self-worth. The SPOT is housed in the Jackson Medical Mall, a former shopping mall that now provides healthcare for the underserved and promotes economic and community development. Tacoma Action Collective (Tacoma, WA) is a partnership of Black community organizers working in grassroots action and education in Washington State. TAC works to to eliminate systemic oppression and structural violence while empowering the people to build autonomous communities rooted in equity and justice. In 2015, the collective staged a die-in at the Tacoma Art Museum in response to the white-washing of the exhibition Art, AIDS, America. VOCAL (Voices Of Community Activists & Leaders) (New York, NY) is a statewide grassroots membership organization that builds power among low-income people affected by HIV/AIDS, hepatitis C, the drug war, homelessness, and mass incarceration in order to create healthy and just communities. VOCAL accomplishes this through community organizing, leadership development, public education, direct services, participatory research and direct action.

Texte traduit vers le français par Hugo B. pour le SéroSyndicat :

Organismes invités:

AIDS Coalition to Unleash Power (ACT UP) NY est groupe non partisan d’individus hétéroclites, unis dans la colère et résolus à prendre des actions directes afin d'éradiquer l’épidémie du sida. L’association ACT UP est née en 1987 en réponse au déni social, à la négligence du gouvernement et à la complaisance du secteur médical durant les années 80. Il fut rapidement évident et nécessaire qu’il leur faille également combattre l’avidité des grandes entreprises, le manque de solidarité face à la crise, ainsi que les différentes formes de stigmatisations et discriminations rencontrées à la fois aux État-Unis et à l’étranger.

ACT UP se bat pour: la mise en place d’investissements continus dans la recherche de nouveaux médicaments et traitements contre le VIH/Sida et ses co-infections sous-jacentes; un accès juste et équitable à la prévention contre le VIH/Sida, aux soins pour les personnes séropositives et séroconcernées, ainsi qu’au système de santé en général; l'éradication des facteurs structurels de l’épidémie du VIH/Sida, notamment la stigmatisation, les discriminations et la pauvreté.

Positive Women’s Network – USA (PWN) est un regroupement national (américain) de femmes vivant avec le VIH et leurs alliés.ées qui existe pour renforcer le pouvoir stratégique de toutes les femmes vivant avec le VIH aux États-Unis . Fondé en 2008 par 28 femmes leaders séropositives et venant d’horizons différents, PWN-USA développe un réseau de portes-paroles et un calendrier politique qui apporte un regard genré sur l’épidémie du VIH aux États-Unis dans une approche profondément ancrée dans la justice sociale et la défense des droits humains.

Chaque jour, PWN-USA inspire, informe et mobilise les femmes vivant avec le VIH en leur fournissant les outils et informations nécessaires pour qu’elles deviennent les leaders de changements qui améliorent les vies de toutes et protègent leurs droits.

  Sero Project est un réseau national de personnes vivant avec le VIH et leurs alliés.ées se battant pour l’affranchissement de toutes formes de stigmatisations et d’injustice. Sero travaille particulièrement à éliminer la criminalisation inappropriée des personnes vivant avec le VIH, que ce soit pour la non-divulgation de leur statut sérologique, l’exposition ou la transmission potentielles ou ressenties du VIH. Sero Project coproduit la biennale de conférences “HIV is Not a Crime” qui fournit aux acteurs.trices canadiens.ennes de la lutte contre le VIH des formations sur les stratégies et meilleures pratiques à employer pour critiquer et influencer un système judiciaire qui criminalise les personnes vivant avec le VIH.

 Safe Place Over Time (The SPOT) (Jackson, MS) se donne pour mission d’offrir des services et des opportunités aux jeunes hommes de Jackson, Mississippi, afin de renforcer leur bien-être, leur autonomisation et leur leadership. Le programme a pour but d’améliorer l’état de santé et de réduire les nouveaux cas de séroconversions au sein de la communauté afro-américaine qui est disproportionnellement affectée par l’épidémie. Le SPOT fait tout son possible pour être un endroit sécuritaire où les jeunes hommes peuvent discuter ouvertement des problèmes et difficultés auxquels ils font face afin d’améliorer leur qualité de vie et renforcer leur confiance en soi. Le SPOT est situé au sein même du Jackson Medical Mall, un ancien centre commercial qui offre aujourd’hui des services de santé aux communautés exclues et qui promeut le développement économique et communautaire.

 Tacoma Action Collective (Tacoma, WA) est un partenariat d’organisateurs communautaires noirs travaillant pour l’action et l’éducation citoyenne dans l’état de Washington. TAC cherche à éliminer l’oppression systémique et la violence structurelle auxquelles font face les communautés noires tout en renforçant leur capacité d’organisation communautaire autonome. L’action de TAC se veut profondément ancrée dans la justice et l’équité. En 2015, le collectif a orchestré un “die-in” au Tacoma Art Museum en réponse à l’invisibilisation des communautés noires au sein de l’exposition “AIDS, ART, AMERICA.”

 VOCAL (Voices Of Community Activists & Leaders) (New York, NY) est un organisme communautaire national américain qui renforce le pouvoir des personnes à faible revenu affectées par le VIH/Sida, par l’hépatite C, par la guerre contre les drogues, par l’itinérance ou encore, par l’incarcération de masse afin de créer des communautés justes et saines. VOCAL atteint ses objectifs à travers l’organisation et la lutte communautaire, le leadership, l’éducation publique, les services aux usagers, la recherche participative et l’action directe.

[berniesrevolution]

On the same day a Philly.com op-ed was published in which Philadelphia District Attorney Larry Krasner (and Mayor Kenney) admitted the failure that was the “War on Drugs,” in the 1980s and ’90s, the DA’s office announced that it is suing 10 pharmaceutical companies in connection with the opioid epidemic and is dropping all outstanding marijuana possession charges.

In just a little over a month since taking office, Krasner has already built on the progress that began under former mayor Michael Nutter’s administration by further reforming the city’s drug policy to the point where getting busted with pot now no longer means a court date is in your future. Krasner says citations are issued approximately 90 percent of the time someone is caught with marijuana.

“What we’re talking about is the 10 percent or so that are being charged as they used to be, as misdemeanors in court,” Krasner said during a press conference Thursday. From now on, the DA will advise his staff not to pursue criminal charges against anyone arrested for marijuana possession in the city. Citations currently range from $25 for possession to $100 for those caught toking up in public.

“I did it because I felt it was the right thing to do,” Krasner said when asked of his motivation. “We could use those resources to solve homicides.”

Additionally, the DA’s office said that it had filed a lawsuit on February 2nd against Big Pharma under Pennsylvania’s Unfair Trade Practices and Consumer Protection Laws for their alleged role in creating the city’s opioid epidemic. The defendants are Purdue Pharma, L.P.; Purdue Pharma, Inc.; The Purdue Frederick Company, Inc.; Allergan Finance, LLC; Cephalon, Inc.; Teva Pharmaceuticals USA, Inc.; Endo Health Solutions, Inc.; Endo Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; and Johnson & Johnson.

(Continue Reading)